vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.
FVCBankcorp, Inc. is the larger business by last-quarter revenue ($16.9M vs $8.6M, roughly 2.0× Sunshine Biopharma Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs -10.6%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $-1.6M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs 6.6%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
FVCB vs SBFM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $8.6M |
| Net Profit | — | $-2.1M |
| Gross Margin | — | 35.3% |
| Operating Margin | 43.7% | -20.9% |
| Net Margin | — | -25.0% |
| Revenue YoY | 4377.5% | -10.6% |
| Net Profit YoY | — | 0.8% |
| EPS (diluted) | $0.31 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | $8.6M | ||
| Q3 25 | $416.0K | $9.4M | ||
| Q2 25 | $15.8M | $9.4M | ||
| Q1 25 | $382.0K | $8.9M | ||
| Q4 24 | $378.0K | $9.6M | ||
| Q3 24 | $412.0K | $8.4M | ||
| Q2 24 | $415.0K | $9.3M | ||
| Q1 24 | $359.0K | $7.5M |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | $5.6M | $-883.8K | ||
| Q2 25 | $5.7M | $-1.8M | ||
| Q1 25 | $5.2M | $-1.2M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $4.7M | $-1.2M | ||
| Q2 24 | $4.2M | $-494.3K | ||
| Q1 24 | $1.3M | $-1.3M |
| Q4 25 | — | 35.3% | ||
| Q3 25 | — | 32.6% | ||
| Q2 25 | — | 36.4% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 32.2% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 25.3% | ||
| Q1 24 | — | 31.2% |
| Q4 25 | 43.7% | -20.9% | ||
| Q3 25 | — | -11.5% | ||
| Q2 25 | 45.9% | -21.8% | ||
| Q1 25 | — | -14.6% | ||
| Q4 24 | — | -21.7% | ||
| Q3 24 | — | -13.1% | ||
| Q2 24 | — | -13.6% | ||
| Q1 24 | — | -17.9% |
| Q4 25 | — | -25.0% | ||
| Q3 25 | 1341.1% | -9.4% | ||
| Q2 25 | 36.0% | -18.8% | ||
| Q1 25 | 1352.1% | -13.3% | ||
| Q4 24 | — | -22.5% | ||
| Q3 24 | 1133.3% | -14.2% | ||
| Q2 24 | 1001.2% | -5.3% | ||
| Q1 24 | 373.3% | -17.0% |
| Q4 25 | $0.31 | — | ||
| Q3 25 | $0.31 | $-0.54 | ||
| Q2 25 | $0.31 | $-0.82 | ||
| Q1 25 | $0.28 | $-0.44 | ||
| Q4 24 | $0.27 | $49.77 | ||
| Q3 24 | $0.25 | $-11.61 | ||
| Q2 24 | $0.23 | $-43.48 | ||
| Q1 24 | $0.07 | $-2.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $253.6M | $23.0M |
| Total Assets | $2.3B | $30.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $253.6M | $23.0M | ||
| Q3 25 | $249.8M | $24.2M | ||
| Q2 25 | $243.2M | $25.7M | ||
| Q1 25 | $242.3M | $22.7M | ||
| Q4 24 | $235.4M | $23.5M | ||
| Q3 24 | $230.8M | $25.0M | ||
| Q2 24 | $226.5M | $23.5M | ||
| Q1 24 | $220.7M | $24.8M |
| Q4 25 | $2.3B | $30.1M | ||
| Q3 25 | $2.3B | $31.5M | ||
| Q2 25 | $2.2B | $32.0M | ||
| Q1 25 | $2.2B | $29.2M | ||
| Q4 24 | $2.2B | $30.6M | ||
| Q3 24 | $2.3B | $30.1M | ||
| Q2 24 | $2.3B | $29.3M | ||
| Q1 24 | $2.2B | $31.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $-1.6M |
| Free Cash FlowOCF − Capex | $23.8M | $-1.6M |
| FCF MarginFCF / Revenue | 140.7% | -18.9% |
| Capex IntensityCapex / Revenue | 0.3% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | $-1.6M | ||
| Q3 25 | $7.6M | $-727.8K | ||
| Q2 25 | $3.3M | $-1.3M | ||
| Q1 25 | $5.4M | $-1.7M | ||
| Q4 24 | $18.2M | $-3.4M | ||
| Q3 24 | $4.7M | $-1.4M | ||
| Q2 24 | $1.6M | $-4.6M | ||
| Q1 24 | $7.2M | $-3.2M |
| Q4 25 | $23.8M | $-1.6M | ||
| Q3 25 | $7.6M | $-735.8K | ||
| Q2 25 | $3.3M | $-1.4M | ||
| Q1 25 | $5.4M | $-1.7M | ||
| Q4 24 | $18.1M | $-3.5M | ||
| Q3 24 | $4.6M | $-1.9M | ||
| Q2 24 | $1.5M | $-5.6M | ||
| Q1 24 | $7.1M | $-3.2M |
| Q4 25 | 140.7% | -18.9% | ||
| Q3 25 | 1818.0% | -7.8% | ||
| Q2 25 | 20.8% | -15.2% | ||
| Q1 25 | 1413.6% | -19.3% | ||
| Q4 24 | 4786.0% | -36.6% | ||
| Q3 24 | 1121.8% | -22.2% | ||
| Q2 24 | 361.2% | -59.7% | ||
| Q1 24 | 1988.3% | -43.1% |
| Q4 25 | 0.3% | 0.0% | ||
| Q3 25 | 0.2% | 0.1% | ||
| Q2 25 | 0.1% | 1.7% | ||
| Q1 25 | 4.2% | 0.1% | ||
| Q4 24 | 37.3% | 1.1% | ||
| Q3 24 | 14.1% | 6.1% | ||
| Q2 24 | 12.8% | 10.5% | ||
| Q1 24 | 3.9% | 0.8% |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
